trastuzumab rezetecan
jiangsu hengrui pharma
['shr-a1811', 'mbc']
impressive waterfall plots for shr-a1811 in her2+ and her2-low mbc. responses observed at all dose levels and in patients receiving prior her2 adcs. #aacr23 
MD, Research Fellow @DanaFarber | @harvardmed | @LaStatale | former @IEOufficiale. Interested in breast oncology, HER2, ADCs & good music. Coffee expert.